Kura Oncology, Inc. (KURA) Stock Forecast
Data as of Sep 16, 2026Healthcare · Current price $11.21 (-3.07%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 13, 2026 | David Dai | UBS | $15.00 | +33.8% |
| Nov 24, 2025 | Etzer Darout | Barclays | $28.00 | +149.8% |
| Nov 14, 2025 | Joseph Pantginis | H.C. Wainwright | $40.00 | +256.9% |
| Nov 22, 2024 | Bradley Canino | Stifel Nicolaus | $11.00 | -1.9% |
| Oct 24, 2024 | David Dai | UBS | $27.00 | +140.9% |
| Oct 14, 2024 | Bradley Canino | Stifel Nicolaus | $19.00 | +69.5% |
| Jun 25, 2024 | Joseph Pantginis | H.C. Wainwright | $32.00 | +185.5% |
| May 23, 2024 | Bradley Canino | Stifel Nicolaus | $28.00 | +149.8% |
| Dec 22, 2023 | Mara Goldstein | Mizuho Securities | $26.00 | +132.0% |
Top Analysts Covering KURA
KURA vs Sector & Market
| Metric | KURA | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.26 | 2.42 |
| Analyst Count | 5 | 8 | 18 |
| Target Upside | +98.9% | +16187.1% | +19.5% |
| P/E Ratio | -2.79 | 3.79 | 38.67 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $7M | $26M | $37M | 4 |
| 2026-12-31 | $12M | $41M | $58M | 8 |
| 2027-03-31 | $10M | $34M | $48M | 4 |
| 2027-06-30 | $10M | $36M | $51M | 4 |
| 2027-09-30 | $11M | $38M | $54M | 5 |
| 2027-12-31 | $11M | $40M | $57M | 4 |
| 2028-12-31 | $351M | $351M | $352M | 11 |
| 2029-12-31 | $287M | $665M | $1.91B | 5 |
| 2030-12-31 | $498M | $1.15B | $3.30B | 5 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $-1.44 | $-0.92 | $-0.07 | 3 |
| 2026-12-31 | $-1.31 | $-0.84 | $-0.06 | 3 |
| 2027-03-31 | $-1.58 | $-1.01 | $-0.07 | 3 |
| 2027-06-30 | $-1.56 | $-1.00 | $-0.07 | 2 |
| 2027-09-30 | $-1.60 | $-1.02 | $-0.07 | 2 |
| 2027-12-31 | $-1.32 | $-0.84 | $-0.06 | 2 |
| 2028-12-31 | $-3.64 | $-1.54 | $3.49 | 10 |
| 2029-12-31 | $0.12 | $0.46 | $1.58 | 4 |
| 2030-12-31 | $0.88 | $3.37 | $11.55 | 4 |
Frequently Asked Questions
What is the analyst consensus for KURA?
The consensus among 5 analysts covering Kura Oncology, Inc. (KURA) is Buy with an average price target of $22.57.
What is the highest price target for KURA?
The highest price target for KURA is $40.00, set by Joseph Pantginis at H.C. Wainwright on 2025-11-14.
What is the lowest price target for KURA?
The lowest price target for KURA is $11.00, set by Bradley Canino at Stifel Nicolaus on 2024-11-22.
How many analysts cover KURA?
5 analysts have issued ratings for Kura Oncology, Inc. in the past 12 months.
Is KURA a buy or sell right now?
Based on 5 analyst ratings, KURA has a consensus rating of Buy (2.00/5) with a +98.9% upside to the consensus target of $22.57.
What are the earnings estimates for KURA?
Analysts estimate KURA will report EPS of $-0.92 for the period ending 2026-09-30, with revenue estimated at $26M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.